Surface Oncology, Inc (NASDAQ:SURF)

CAPS Rating: No stars

Caps

How do you think SURF will perform against the market?

Add Stock to CAPS Watchlist

All Players

2 Outperform
5 Underperform
 

All-Star Players

0 Outperform
5 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top SURF Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

shanelofgren (31.38)
Submitted September 26, 2018

Bet: ADA -> cAMP -> -> CSK -| LCK -> TCR axis is very solidly founded in experimental evidence from many groups. CD73's role in producing ADA also very solid. It's widely enough expressed in many solid tumor indications. It is relevant to T cells at… More

TerryHogan (99.97)
Submitted November 10, 2018

I'm no oncologist, but as far as I can tell, the R&D department at this company heats their office by burning cash.

SURF VS S&P 500 (SPY)

SURF Summary

Recent Community Commentary

Read the most recent pitches from players about SURF.

Recs

1
Member Avatar TerryHogan (99.97) Submitted: 11/10/2018 2:08:05 AM : Underperform Start Price: $8.12 SURF Score: -9.44

I'm no oncologist, but as far as I can tell, the R&D department at this company heats their office by burning cash.

Recs

1
Member Avatar shanelofgren (31.38) Submitted: 9/26/2018 3:49:21 PM : Outperform Start Price: $10.32 SURF Score: -8.81

Bet: ADA -> cAMP -> -> CSK -| LCK -> TCR axis is very solidly founded in experimental evidence from many groups. CD73's role in producing ADA also very solid. It's widely enough expressed in many solid tumor indications. It is relevant to T cells at all activation stages (vs. the agonist antibodies, whose use may be too narrow). Thus betting that single agent CD73 inhibition will show efficacy, lead to combination trials with strong responses with other agents. Feels like it's late to the party, but this may be the combo w/ PD1 + (maybe CTLA4) that really moves the survival curve the next big chunk up and to the right.

Risks are safety. The breadth of relevance also means a breadth of off target opportunities to exacerbate simmering autoimmunity.

Risks are also CD47. Don't really know a lot about it or its relevance. Science is much newer, less validated. Can phagocytes really play a relevant role in a anti-tumor responses in a broad set of patients? Unclear.

Recs

0
Member Avatar saxjax (53.59) Submitted: 7/11/2018 8:06:06 PM : Outperform Start Price: $16.64 SURF Score: -44.04

SURF, the calm waves(up & down) but long haul will be a steady big wave

Leaderboard

Find the members with the highest scoring picks in SURF.

Score Leader

sln

sln (72.51) Score: +17.67

The Score Leader is the player with the highest score across all their picks in SURF.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
TheSlightEdge 99.09 11/5/2018 Underperform 3W $8.44 +1.18% -2.52% -3.71 0 Comment
cheev 99.96 11/16/2018 Underperform 3W $8.16 +4.66% -2.78% -7.44 0 Comment
cashole 99.86 11/2/2018 Underperform 1Y $8.05 +6.09% -1.75% -7.84 0 Comment
shanelofgren 31.38 9/26/2018 Outperform 5Y $10.32 -17.25% -8.44% -8.81 1 Comment
TerryHogan 99.97 11/12/2018 Underperform 5Y $8.12 +5.17% -4.26% -9.44 1 Comment
TheGreatSatan 100.00 11/2/2018 Underperform 5Y $7.27 +17.47% -3.41% -20.88 0 Comment
saxjax 53.59 7/12/2018 Outperform 5Y $16.64 -48.68% -4.64% -44.04 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for SURF.

Advertisement